In the News
Will the FTC’s Amgen Suit Ignite Future Pharmaceutical M&A Conflicts?
With M&A activity in the life sciences sector heating up, the latest dispute in the space may affect the future of pharmaceutical acquisitions. How will the FTC's recent case against Amgen ignite future M&A conflicts, and where can experts assist in the litigation process?
What’s Next for Microsoft and Activision’s Antitrust Battle After EU and UK Decisions
The biggest gaming deal in history has hit another regulatory roadblock. As Microsoft continues to seek government approval for their acquisition of Activision, regulators in the UK and EU have announced conflicting opinions on the deal, creating a confusion about what’s to come for the merger.
Expert Assessment: How the Crypto Crackdown Could Propel Conflict
As crypto market players continue looking for concrete guidance regarding industry regulations, how will regulators respond to their requests for action? Read fintech expert Dr. Peter Vinella's insights on what he thinks is next for those in the digital assets space.
Insights & News
April 4, 2023 — Press Release
WIT Legal Expands Life Sciences Practice to Address Increase in Litigation Targeting Pharmaceutical, Biotechnology, and Healthcare Technology Companies
The company has a reputation for building diverse teams of leading experts across trending areas of litigation and is committed to affiliating with the most qualified experts in emerging markets.
February 22, 2023 — Blog
Pharmaceutical Industry’s Drug Patent Cliffs Approach, Giving Rise to the Need for Highly Credentialed Experts
Several patents from the pharmaceutical industry’s best-selling drugs are set to expire. As a result, competition intensifies with copycat drugs already in the works and counsel strategizing on protecting monetized IP.
July 14, 2021 — Blog
FDA Approvals, Controversial Therapeutics, and the Experts Needed for Litigation
Therapeutics are some of the most complicated, most regulated, and most litigated products existing in the market today. Any inconsistencies to the qualification and validation protocols of the product can cause undue harm, lasting damage, and unlimited claims of liability.
Load More Loading...